Zim Laboratories Releases Q4 & FY26 Earnings Call Transcript; EU GMP Inspection Outcome Expected Positively
Zim Laboratories released its Q4 & FY26 earnings call transcript. The company expects a positive outcome from its recent EU GMP re-inspection. FY26 revenue was stable at ₹374.4 crore, impacted by geopolitical issues in MENA. Q4 revenue was ₹105.3 crore. Significant investments were made in NIP and OTF platforms.
The EU GMP compliance is critical for Zim Laboratories' international business and market access. A positive outcome significantly impacts future revenue streams and market penetration.
The company expects a positive outcome from the EU GMP inspection, has completed CAPA implementation, and is seeing sequential business momentum, indicating a positive outlook.
Zim Laboratories Limited has released the transcript of its Q4 and FY26 Earnings Conference Call, held on May 20, 2026. The call focused on the company's progress with its EU GMP remediation and CAPA implementation. The Chairman and Managing Director, Dr. Anwar Daud, reported substantial completion of CAPA implementation and addressed outstanding regulatory queries. A regulatory re-inspection by German and Portuguese authorities was conducted from May 4 to May 7, 2026, with a positive outcome anticipated.
Operationally, FY26 was a year of resilience, with full-year revenue remaining broadly in line with the previous year. The MENA region experienced an estimated revenue impact of ₹20 crore due to geopolitical disruptions. The core pharmaceutical business demonstrated healthy sequential traction, with NIP and OTF segments showing improved performance in Q4.
Financially, for Q4 FY26, total operating income was approximately ₹105.3 crore (INR 1,053 million), with EBITDA at approximately ₹13.4 crore (INR 134 million) and Profit After Tax at ₹3.7 crore (INR 37 million). For the full financial year FY26, total operating income stood at approximately ₹374.4 crore (INR 3,744 million), with EBITDA at approximately ₹41.4 crore (INR 414 million) and PAT at ₹5.8 crore (INR 58 million). Investments of ₹31.1 crore (INR 311 million) were allocated to BE studies and registrations for the NIP and OTF platforms.
The company has also strengthened its leadership team with several senior appointments and is optimistic about FY27, anticipating a stronger performance post-EU GMP reinstatement. The company is also progressing on new product developments, including an anticoagulant product and urology and gastrointestinal products, with commercialization expected in Q4 FY26 and FY28 respectively.
What to do with a filing like this
Zim Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zim Laboratories Limited. Read the original for the full detail.